Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need.

The conversation explores identity disruption after brain injury, the unintended effects of rigid recovery timelines, and the importance of continuity in understanding symptoms over time. Dr. Gurin also discusses how neurodevelopmental traits such as ADHD shape vulnerability and treatment response, when stimulant medications can be appropriate after concussion, and why breaking complex presentations into treatable components often matters more than assigning a single diagnosis.

Lindsey Gurin, MD, is Assistant Professor in the Departments of Neurology, Psychiatry, and Rehabilitation Medicine at NYU Langone Health, and Director of the Neurology/Psychiatry Residency Program.

▶️ Watch Insights on Psychiatry on YouTube

00:00 Brain Injury and Identity
01:27 What Is the Psychiatry–Neurology Double Board?
02:41 Why PTSD and TBI Overlap
03:28 What “Shell Shock” Really Means
06:00 When Concussion Symptoms Don’t Go Away
07:25 Life Before vs After Brain Injury
08:46 ADHD as a Hidden Risk Factor
10:28 Using Stimulants After Brain Injury
12:40 Rethinking “Post-Concussion Syndrome”
13:27 The Future of Neuropsychiatric Care

This episode is intended for psychiatrists and other clinicians caring for patients with complex neuropsychiatric presentations at the intersection of psychiatry and neurology.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Michael Bogenschutz, MD, explains how psychedelic-assisted treatments may offer new options for patients with severe, treatment-refractory psychiatric conditions. He discusses why standard approaches often fall short for complex cases, how psychedelics like psilocybin and MDMA differ from conventional medications, and what careful screening and clinical structure make these treatments safe and effective.

Drawing on randomized clinical trials and years of clinical experience, Dr. Bogenschutz describes how psychedelic treatments can produce durable symptom improvement in disorders such as alcohol use disorder and trauma-related conditions. He also explores unresolved scientific questions, including whether the psychedelic experience itself is necessary for therapeutic benefit.

Michael Bogenschutz, MD, is Professor of Psychiatry and Director of the Center for Psychedelic Medicine at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:00 A Remarkable Case: Sustained Sobriety After Psilocybin Treatment
00:39 Introducing Dr. Michael Bogenschutz
01:04 Why Psychiatry Is Re-Examining Psychedelics
02:50 Safety, Screening, and Managing the Psychedelic Experience
03:45 Landmark Trial: Psilocybin for Alcohol Use Disorder
06:16 How Psychedelics Work: Neuroplasticity vs. Subjective Experience
08:53 Can Non-Psychedelic Analogs Deliver the Same Benefits?
11:47 MDMA, Fear Reduction, and Emotional Processing
13:44 Who Benefits Most? A Composite of Treatment-Refractory Patients
15:45 The Future of Psychedelic Psychiatry at NYU

This episode is intended for psychiatrists, mental health clinicians, and others interested in complex and treatment-resistant psychiatric conditions.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Lenard Adler, MD, explains how clinicians can safely and effectively treat ADHD when bipolar disorder and addiction are also in the picture. He addresses how to distinguish chronic ADHD symptoms from episodic mood disorders, why bipolar disorder is often missed in adults referred for depression or attention problems, and how substance use complicates both diagnosis and medication selection.

Dr. Adler also shares guidance on identifying red flags for diversion or misuse, setting appropriate expectations for medication trials, and navigating the limits of current treatment guidelines. The episode closes with a look toward emerging directions in ADHD treatment, including research on emotional dysregulation, executive function deficits, and next-generation neurofeedback approaches.

Lenard Adler, MD, is Pottash Professor of Psychiatry and Director of the Adult ADHD Program at NYU Langone Health

▶️ Watch Insights on Psychiatry on YouTube

00:00 Why ADHD, Bipolar Disorder, and Addiction Must Be Treated Together
01:02 What Makes These ADHD Cases So Difficult
02:05 ADHD vs. Bipolar Disorder: Key Diagnostic Distinctions
04:43 The Link Between ADHD and Addiction
05:53 Using Stimulants Safely When Substance Use Is a Concern
07:57 Choosing Stimulants vs. Non-Stimulants
10:07 How Severity and Comorbidity Shape Treatment Decisions
12:06 The Limits of Guidelines and Biomarkers in ADHD Care
15:34 Executive Function and Emotional Dysregulation
16:13 Where ADHD Treatment Is Headed Next

This episode is intended for psychiatrists, mental health clinicians, and others interested in complex adult ADHD presentations.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Ayana Jordan, MD, PhD, discusses how precision psychiatry must expand beyond biology to address the social, cultural, and structural realities shaping addiction and mental health care for historically underrepresented patients. The conversation explores how trauma, poverty, housing instability, health literacy, and stigma interact with substance use and serious mental illness—and why traditional clinic-based models often fail to meet patients where they are.

Dr. Jordan describes the work of the Jordan Wellness Collaborative, including partnerships that integrate addiction treatment into primary care, community settings, and faith-based institutions. She explains how peer facilitators, housing support, and trusted community spaces can dramatically improve engagement, retention, and outcomes. Looking ahead, she reflects on how emerging tools—from AI-supported care models to novel treatments for addiction—may further transform access and equity in psychiatric care.

Ayana Jordan, MD, PhD, is the Barbara Wilson Professor of Psychiatry at NYU Grossman School of Medicine and Principal Investigator of the Jordan Wellness Collaborative.

▶️ Watch Insights on Psychiatry on YouTube

TOPICS

• Expanding precision psychiatry beyond biological models
• Structural barriers to care: housing, literacy, and stigma
• Addiction treatment for historically underrepresented communities
• Integrating care into primary care, community, and faith-based settings
• The role of peer facilitators and lived experience in treatment
• Trust, safety, and engagement for patients with complex needs
• Future directions: AI, novel addiction treatments, and workforce training

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Dan Iosifescu, MD, discusses why bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment. Dr. Iosifescu argues that standard approaches often fall short because symptom suppression is mistaken for recovery, short-term improvement is confused with durable treatment, and mixed episodes expose the limits of one-size-fits-all care.

The conversation explores the clinical dangers of mixed episodes, the challenge of recognizing them, and the importance of moving deliberately from acute stabilization to sustainable long-term treatment. 

Dan Iosifescu, MD, is Director of Clinical Research at the Nathan Kline Institute and Director of the Mood Disorders Clinical and Research Program at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:33 Introduction
01:22 Challenges of Treating Bipolar Depression
02:58 Case Study: The Impact of Bipolar Depression
05:01 Novel Treatments and Approaches
07:23 Understanding and Managing Mixed Episodes
13:44 Future Directions in Bipolar Disorder Treatment
16:09 Innovative Research at NYU Psychiatry
22:33 Conclusion and Final Thoughts

This episode is intended for psychiatrists, mental health clinicians, and others interested in treatment-resistant forms of depression and bipolar disorder.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

Joshua Berman, MD, PhD, discusses how careful evaluation, patient priorities, and risk-benefit tradeoffs guide the use of interventional treatments when conventional approaches fall short. Dr. Berman also explains how tools such as ketamine, TMS, ECT, and neurofeedback can be used strategically—sometimes in sequence or combination—to address different vulnerabilities within mood-related brain circuits.

Dr. Berman is Associate Professor of Psychiatry and Director of Interventional Psychiatry at NYU Langone Health.

▶️ Watch Insights on Psychiatry on YouTube

00:47 What Is Interventional Psychiatry?
02:33 Evaluating Treatment-Resistant Presentations
06:31 Precision, Patient Priorities, and Clinical Judgment
09:35 Sequencing and Combining Interventions
10:40 Limits of Treatment Guidelines
12:18 The Future of Interventional Psychiatry
13:23 Emerging Technologies: Neurofeedback and Focused Ultrasound
17:15 Building a Comprehensive Interventional Program
18:13 Tools vs. Understanding Brain Circuits

This episode is intended for psychiatrists, mental health clinicians, and others interested in interventional approaches to complex psychiatric disorders.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

To kick off Season 4, Charles Marmar, MD, explains how precision psychiatry is reshaping the way clinicians and researchers think about diagnosis, treatment selection, and the underlying biology of psychiatric disorders. This conversation is a overview of where the field stands today—including emerging molecular markers, biologically informed subtypes, and new translational approaches inspired by oncology and other precision-based specialties.

Dr. Marmar is Chair of Psychiatry at NYU Grossman School of Medicine, and Director of the Center for the Study of Alcohol Use Disorder and Traumatic Stress.

▶️ Watch Insights on Psychiatry on YouTube

In this episode, Dr. Marmar outlines current work on:

• Molecular and genomic signatures that may distinguish patient subtypes
• Clinical trials examining targeted treatments for alcohol use disorder
• The development of proxy “brain biopsy” methods such as exosomal analyses and iPSC-derived organoids
• How converging biological data could eventually support more individualized treatment planning

This discussion reflects ongoing efforts at NYU Langone Health to move psychiatry toward a more mechanism-based, biologically grounded model of care, while acknowledging the complexity and early stage of the work.

This episode is intended for psychiatrists, mental health clinicians, and others interested in the treatment of complex psychiatric disorders.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front lines: a patient whose depression was treated with the help of a brain biopsy, why PTSD and depression aren’t one-size-fits-all, and how quantum computing could radically accelerate psychiatric research.

🔍 Topics Covered

00:00 Introduction
02:24 Personalized Treatment Approaches
05:13 Challenges in Precision Psychiatry
11:12 The Role of Genomics and Brain Imaging
23:35 Digital Psychiatry and AI
25:57 Quantum Computing in Psychiatry
33:04 Future of Precision Psychiatry
37:22 Conclusion

📚 Related Resources

Charles Marmar, MD – NYU Faculty Profile
NYU Langone Psychiatry
Adriana Heguy, PhD – NYU Faculty Profile
Javad Shabani, PhD – NYU Faculty Profile

🙌 Support & Subscribe

If this episode challenged your thinking, like, share, and subscribe to help bring smart, science-forward conversations to a wider audience.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

There’s a care model for schizophrenia that actually works—why isn’t it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you bring humanity, structure, and innovation to a population too often left behind.

Also discussed:

• The first novel schizophrenia drug in over 50 years (Cobenfy)
• Why clozapine is underused—and how that may finally change
• The potential of brain imaging and biomarkers in psychiatric treatment
• What a real community mental health system looks like
• Why trust, not just treatment, is essential for recovery

🔍 Topics Covered

00:00 Introduction
00:30 Dr. Frankle's Current Work
01:08 Advancements in Schizophrenia Research
02:29 Challenges and New Treatments in Schizophrenia
05:02 Precision Medicine in Psychiatry
05:59 PET Scans and Brain Energetics
09:46 Barriers to Effective Treatment
11:51 Clozapine and Treatment Access
13:38 Wraparound Services and Community Care
14:46 Early Screening and Public Health Interventions
18:32 Mandated Treatment and Patient Engagement
30:08 Homelessness and Mental Health
34:54 Future Directions in Schizophrenia Treatment
38:09 Conclusion

📚 Related Resources

W. Gordon Frankle, MD, MBA
Schizophrenia care at NYU Langone
NYU Langone Hospital—Brooklyn
3 Things to Know About Cobenfy (Yale Medicine)

🙌 Support & Engage

If you enjoyed this episode, please like, share, and subscribe to support real conversations about transforming mental health care.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle

How could a single psychedelic treatment cause lasting change? Joshua Siegel, MD, PhD, is on a mission to find out. A leading expert on neuroimaging and neuropsychopharmacology at NYU Langone’s Center for Psychedelic Medicine, Dr. Siegel unpacks how psilocybin may spark neuroplasticity and reshape the depressed brain. He also gives us an inside look at the race to develop non-hallucinogenic psychedelic analogs. 

Dr. Siegel is an assistant professor at NYU Grossman School of Medicine.

🔍 Topics Covered:

00:00 Introduction
00:15 Dr. Siegel's Current Work
01:01 Past Research and Human Psilocybin Imaging Study
02:39 Understanding Brain Changes and Biomarkers
06:13 Mechanisms of Action and Plasticity
12:51 Surprising Findings and Context Dependence
16:34 Challenges and Future Directions in Psychedelic Research
20:46 Advanced Imaging and Personalized Treatment Plans
24:15 Setbacks and Lessons in Psychedelic Medicine
28:40 Emerging Areas in Neuropsychopharmacology
31:46 Conclusion

📚 Related Resources:

Joshua Siegel, MD, PhD 
NYU Langone Health’s Center for Psychedelic Medicine
The Multidisciplinary Association for Psychedelic Studies (MAPS)
“Psychedelic and Dissociative Drugs as Medicines” (NIH) 

🙌 Support & Engage: Enjoyed this episode? Like, comment, and share to support science-based conversations about mental health.

🔔 Don’t forget to subscribe for more interviews with top psychiatric researchers.

This discussion is for educational purposes and does not substitute for individual clinical judgment or patient care.

Senior Producer: Jon Earle